From Intractable
To Investable

Women’s health is one of the largest underdeveloped opportunities in life sciences and the scientific, clinical and commercial infrastructure supporting innovation in this space has historically lagged disease burden. Therapeutic areas such as obesity and oncology, fields once considered scientifically complex or commercially uncertain, have become established areas of investment once biological understanding, clinical development strategy, and regulatory pathways mature. Women’s health is now approaching a similar inflection point.

 

Weatherden is bringing together investors, leaders from biotech, pharma and academia to explore how smarter clinical development and regulatory strategy can unlock the next wave of innovation in Women’s Health.

​

Through expert panels and interactive roundtables, we’ll tackle critical challenges:

◐ Defining the right patient populations
◐ Generating regulatory‑ready evidence
◐ Evaluating risk-benefit specifically for women

​

 

​

​